Published in:
01-01-2013
Perioperative assessment of platelet function by Thromboelastograph® Platelet Mapping™ in cardiovascular patients undergoing non-cardiac surgery
Authors:
Davide Cattano, Alfonso V. Altamirano, Husnu E. Kaynak, Carmen Seitan, Rita Paniccia, Zhongxue Chen, Hanwen Huang, Domenico Prisco, Carin A. Hagberg, Evan G. Pivalizza
Published in:
Journal of Thrombosis and Thrombolysis
|
Issue 1/2013
Login to get access
Abstract
Five percent of patients on dual antiplatelet therapy after coronary artery stent implantation will need non-cardiac surgery within the first year of therapy, and many more will need surgery later on. A function assay that evaluates platelet reactivity and inhibition by drug therapy is beneficial for such patients. Platelet Mapping assay (PM™) using the TEG® analyzer was tested in surgical patients. After IRB approval, 60 patients on combined aspirin and clopidogrel therapy were consented and enrolled. The TEG® maximal amplitude (MA) and the percentage (%) platelet inhibition were recorded and analyzed. Fifty-seven patients (mean age 65.7 ± 10.9 years) had preoperative data only. Distribution of preoperative ADP (43.6 ± 24.4 %) and AA inhibition (52.8 ± 30.2 %) was determined, as well as for the preoperative MA ADP (43.1 ± 15.9 mm) and MA AA (37.2 ± 19.6 mm), showing an offset of the effect of both medications starting from day 3. Patients with complete pre- and postoperative data were stratified depending on duration off antiplatelet therapy (≤3 days, 3–7 days and >7 days): n = 27, ADP % preop inhibition (43.2 ± 21.6 %), ADP % postop inhibition (32.3 ± 18.3 %), p = 0.048. Distribution of immediate pre- and post- ADP and AA % inhibitions, showing a possible reduction in Δ of inhibition for clopidogrel at 3 days, were also assessed. Conclusion: According to the findings, the TEG® PM™ assay might be a feasible approach to objectively evaluate the effects of aspirin and clopidogrel during the perioperative period and potentially guide drug management.